|
|
 |
|
Viewing report
|
|
|
|
Stakeholder Insight: Invasive Fungal Infections - Options Outweigh Replacements
Datamonitor, Jan 2004, Pages: 390
Systemic fungal infections lead to considerable morbidity and mortality in patients with suppressed immune systems, such as HIV, cancer and transplant patients.
While the increasing size of such population groups has driven the need for effective treatments and prophylaxis, the advent of HAART and associated declining incidence among HIV patients has limited market growth.
Scope of Report:
Overview of the epidemiology of invasive fungal infections, including detailed numerical breakdowns of at-risk patient groups and main risk factors
Description of the main currently available antifungal products, including 2002 sales, percentage product usage and physician perception of products
Highlights:
The last fifteen years has seen a rapid expansion in the range of antifungal products available for the treatment of systemic mycoses. Consequently, considerations such as oral availability and cost are starting to exert an influence, although efficacy and side-effects remain the primary factors affecting product usage.
Reasons to Purchase:
Assess the total patient population at risk of acquiring an invasive fungal infection, and the factors which contribute to this increased risk
Analyze factors contributing to prescription decisions, including detailed product profiles and usage trends of the main systemic antifungal product
Understand trends in antifungal prophylaxis, including the total patient population receiving prophylaxis, and success rates
Scope of Report:
Analysis based on a survey of 180 physicians, conducted across seven major markets - US, Japan, France, Germany, Italy, Spain and the UK
Transcripts of interviews with key opinion leaders
Report Highlights:
The treatment of invasive fungal infections is changing from a specialty area, focused on specific subpopulations, to an increasingly high volume practice targeting large numbers of hospitalized and community based immunocompromised individuals.
Despite recent advances in treatment, mortality rates of invasive fungal infections remain unacceptably high. Fast, accurate diagnosis remains a key obstacle in the two most common pathogen groups, Candida and Aspergillus.
Region: Global
Customers who bought this item also bought
Strategic Perspectives: Invasive Fungal Infections - Cancidas and Vfend drive physician switching
Treatment Algorithms 2001: Venous Thromboembolism - Prophylaxis
Superficial Fungal Infections. Brand Awareness - the key to success?
Advances in the Treatment of Serious Systemic Fungal Infections--An Update
Pipeline Insight: Antithrombotics - Reaching The Untreated Prophylaxis Market
Pipeline Insight: HIV - Extending Treatment Options
Stakeholder Opinions: Nosocomial Infections - The Need for New Gram-negative Drugs
Diabetes: Opinion Leader Forum - Expert's Views and Perspectives on Diagnosis, Treatment, Product Performance, and Closing the Need Gap
Stakeholder Insight: Prostate Cancer - Hormone-Refractory Patients Still Waiting For Treatment Breakthroughs
Stakeholder Opinion: Atopic Dermatitis - A High Level of Unmet Need Creates Market Opportunities
Stakeholder Insight: Parkinsons Disease - Evidence of neuroprotection essential to progress treatment dynamics
Psoriasis - Biologics Impact Treatment Regimes Across The Globe
|
|
|
|
